About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.5B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Worth Venture Partners, LLC Portfolio

Follow Worth Venture Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Worth Venture Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Worth Venture Partners, LLC with notifications on news.